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In this issue of the Journal, there is an interesting study by Larsen and coworkers 1 . The authors provide evidence that in pulmonary hypoxia a new mechanism might be operational that explains the deterioration of heart function in primary pulmonary hypertension. The authors chronically exposed mice to 10% oxygen in order to mimic hypoxia in patients. The authors had noted in previous studies that this degree of pulmonary hypoxia leads to slower cardiac relaxation, putatively due to reduced phosphorylation of phospholamban on amino acid serine 16. In the present report they provide evidence that the activity of phosphatase 2A but not phosphatase 1 is enhanced in sarcoplasmic reticulum-enriched membranes from these hearts. This led to reduced phosphorylation of phospholamban, which could explain reduced cardiac The role of serine/threonine phosphatases in the heart has gained considerable attention. For instance, it is well known that increased activity of calcineurin, also known as phosphatase 2B, leads to cardiac hypertrophy. If the animals are treated with an inhibitor on the enzyme (cyclosporine A), this hypertrophy is prevented. Also, if transgenic animals are engineered with additional overexpression of MCIP, a protein inhibitor of calcineurin, this hypertrophy can also be antagonised (for review 2 ). Moreover, there is evidence that increased expression of the catalytic subunit of PP1α occurs in human heart failure 3, 4 , and mice with overexpression of the catalytic subunit of PP1α also exhibit hypertrophy, fibrosis and increased mortality 5 . If the phosphatase activity is reduced by use of an adenovirus, the phenotype of the animals is rescued 5 . On the other hand, if the protein inhibitor of PP1, namely I-1, is knocked out, increased PP1 activity and cardiac hypertrophy is noted 5 . Similarly, if I-2 of PP1 is overexpressed, the heart exhibits a hypercontractile state under basal conditions, probably because the phosphorylation state of phospholamban is enhanced 6 .
Some studies on the cardiac role on PP2A, which occurs as a dimer or trimer (Fig. 1) , have also been performed (for review 7 ). For instance, overexpression of a dominant negative mutant of the structural A-subunit of PP2A increases PP2A activity, and this leads to cardiac hypertrophy 8 . The function of the regulatory Bsubunit has not yet been studied by overexpression in the heart (Fig. 1) .
Moreover, inhibition of PP2A with a drug, fostriecin, protected rabbit hearts against ischemia 9 . If the catalytic subunit of PP2A is overexpressed, this leads to cardiac hypertrophy, impaired cardiac function and decreased phosphorylation of cardiac regulatory proteins like phospholamban and the inhibitory subunit of troponin 10 . In addition, in at least some animal models of cardiac hypertrophy, increased activity of PP2A has been observed 11 . Thus, it is interesting that PP2A
can apparently also be regulated by hypoxia (see Fig. 1 ). One can speculate that a drug such as fostriecin that is able to decrease PP2A activity might be beneficial in primary pulmonary hypertension. However, this drug is usually used in patients suffering from carcinoma. In fact, fostriecin has other effects besides phosphatase inhibition, including effects on topoisomerases 12 . Hence, PP2A might be an interesting target for future pharmaceutical research to design organic compounds that selectively inhibit this enzyme. While it is well established that proteins like I-1 PP2A or I-2 PP2A exist 13 , it cannot be predicted whether these would be useful for gene therapy of primary pulmonary hypertension or chronic obstructive pulmonary disease as they are known to increase PP1 activity to some extent 14 . In summary, the paper by Larsen et al.
opens a new field of research into a pathophysiological role of PP2A. PP2A is composed of three subunits (A, B, C = catalytic subunits). Heart failure and/or hypoxia lead to increased expression of the C subunit and thereby increased phosphatase activity, which results in decreased phosphorylation and hence decreased function of cardiac regulatory proteins. For further details see text.
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